Inqovi for AML treatment ...

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...

Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results ...

Panelists discuss how implementing oral regimens faces significant operational barriers including formulary restrictions, prior authorization requirements, insurance coverage differences between ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

Immunotherapy has revolutionized the way physicians treat patients with cancer. This form of cancer treatment aims to direct the immune system toward the rapidly growing tumor. As cancer progresses, ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Analysis of 2823 adult patients with acute myeloid leukemia (AML) revealed that overall survival decreases almost linearly with increasing age across all European LeukemiaNet (ELN) genetic-risk groups ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...